RT Journal Article
SR Electronic
T1 Impact of Social Vulnerability on COVID-19 Incidence and Outcomes in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.10.20060962
DO 10.1101/2020.04.10.20060962
A1 Nayak, Aditi
A1 Islam, Shabatun J.
A1 Mehta, Anurag
A1 Ko, Yi-An
A1 Patel, Shivani A.
A1 Goyal, Abhinav
A1 Sullivan, Samaah
A1 Lewis, Tené T.
A1 Vaccarino, Viola
A1 Morris, Alanna A.
A1 Quyyumi, Arshed A.
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.04.10.20060962.abstract
AB Importance Prior pandemics have disparately affected socially vulnerable communities. Whether regional variations in social vulnerability to disasters influence COVID-19 outcomes and incidence in the U.S. is unknown.Objective To examine the association of Social Vulnerability Index (SVI), a percentile-based measure of county-level social vulnerability to disasters, and its sub-components (socioeconomic status, household composition, minority status, and housing type/transportation accessibility) with the case fatality rate (CFR) and incidence of COVID-19.Design Ecological study of counties with at least 50 confirmed COVID-19 cases as of April 4th, 2020. Generalized linear mixed-effects models with state-level clustering were applied to estimate county-level associations of overall SVI and its sub-component scores with COVID-19 CFR (deaths/100 cases) and incidence (cases/1000 population), adjusting for population percentage aged ≥65 years, and for comorbidities using the average Hierarchical Condition Category (HCC) score. Counties with high SVI (≥median) and high CFR (≥median) were identified.Setting Population-based study of U.S. county-level data.Participants U.S. counties with at least 50 confirmed COVID-19 cases.Main outcomes and measures COVID-19 CFR and incidence.Results Data from 433 counties including 283,256 cases and 6,644 deaths were analyzed. Median SVI was 0.46 [Range: 0.01-1.00], and median CFR and incidence were 1.9% [Range: 0-13.3] and 1.2 per 1000 people [Range: 0.6-38.8], respectively. Higher SVI, indicative of greater social vulnerability, was associated with higher CFR (RR: 1.19 [1.05, 1.34], p=0.005, per-1% increase), an association that strengthened after adjustment for age>65 years and comorbidities (RR: 1.63 [1.38, 1.91], p<0.001), and was further confirmed in a sensitivity analysis limited to six states with the highest testing levels. Although the association between overall SVI and COVID-19 incidence was not significant, the SVI sub-components of socioeconomic status and minority status were both predictors of higher incidence and CFR. A combination of high SVI (≥0.46) and high adjusted CFR (≥2.3%) was observed in 28.9% of counties.Conclusions and Relevance Social vulnerability is associated with higher COVID-19 case fatality. High social vulnerability and CFR coexist in more than 1 in 4 U.S. counties. These counties should be targeted by public policy interventions to help alleviate the pandemic burden on the most vulnerable population.Question Is county-level social vulnerability to disasters associated with the case fatality rate (CFR) and incidence of SARS-CoV-2 infection during the COVID-19 pandemic in the U.S.?Findings Each percentile increase in county-level social vulnerability, measured using the Social Vulnerability Index (SVI), was associated with a 63% higher CFR after adjusting for age and comorbidities. Both CFR and incidence of COVID-19 were significantly higher in counties with lower socio-economic status and higher proportion of minority populations.Meaning U.S. counties with higher social vulnerability are experiencing greater mortality rates during the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementS.J.I. is supported by NIH grants T32 HL130025 and T32 HL007745-26A1. A.M. is supported by American Heart Association grant 19POST34400057 and the Abraham J. & Phyllis Katz Foundation. S.S. is supported by NIH grants K12HD085850 & L30HL148912. A.A.M. is supported by funding from NIH/NHLBI K23 HL124287 and the Robert Wood Johnson Foundation (Harold Amos Medical Faculty Development Program). A.A.Q. is supported by NIH grants 1P20HL113451-01, 1R61HL138657-02, 1P30DK111024-03S1, 5R01HL095479-08, 3RF1AG051633-01S2, 5R01AG042127-06, 2P01HL086773-08, U54AG062334-01, 1R01HL141205-01, 5P01HL101398-02, 1P20HL113451-01, 5P01HL086773-09 1RF1AG051633-01, R01 NS064162-01, R01 HL89650-01, HL095479-01, 1DP3DK094346-01, 2P01HL086773, and American Heart Association grant 15SFCRN23910003.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the analysis of this manuscript is publicly available. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Geographic-Variation/GV_PUF https://coronavirus.jhu.edu/ https://svi.cdc.gov/ https://covidtracking.com/